Yazar "Can, Yesim" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Increased Plasma Nesfatin-1 Levels in Patients with Obsessive Compulsive Disorder
    (Kure Iletisim Grubu A S, 2012) Bez, Yasin; Ari, Mustafa; Ozturk, Oktay Hasan; Oktar, Suleyman; Can, Yesim
    Increased plasma nesfatin-1 levels in patients with obsessive compulsive disorder Objective:To determine and compare the plasma nesfatin-1 (a satiety peptide) levels of patients with obsessive compulsive disorder (OCD) and healthy control subjects. Method: Plasma nesfatin-1 levels of 31 patients with OCD (18 females, 13 males) and 28 healthy control subjects (16 females and 12 males) similar to the study group in terms of weight, age, and gender were measured in this study. Severity of obsessions and compulsions both in OCD patients and control subjects were determined by using Yale-Brown Obsessive Compulsive Scale (Y-BOCS). ELISA method was used to measure plasma nesfatin-1 levels. Results: Median plasma nesfatin-1 levels in patients with OCD and healthy control subjects were 4.61 ng/ml (min-max: 1.28-8.11) and 2.0 ng/ml (min-max: 0.11-4.98) respectively. The observed difference in plasma nesfatin-1 levels between two groups was statistically significant (p<0.001). No statistically significant correlation was observed between Y-BOCS scores and plasma nesfatin-1 levels either in the study group (r=0.205, p=0.27) or in the control group (r=0.335, p=0.071). Conclusion: Increased plasma nesfatin-1 levels observed in patients with OCD suggest a potential role to nesfatin-1 in anxiety states besides its previosly known anorexigenic effects.
  • [ X ]
    Öğe
    Plasma Nesfatin-1 Level May Be Associated with Disease Severity in Patients with Panic Disorder
    (Kure Iletisim Grubu A S, 2010) Bez, Yasin; Ari, Mustafa; Ozturk, Oktay Hasan; Oktar, Suleyman; Can, Yesim; Sogut, Sadik
    Objective:We have compared the plasma levels of the recently discovered peptide hormone nesfatin-1 between patients with panic disorder (PD) and healthy control subjects. Method: The subjects in the patient group were selected from the patients who presented to the psychiatry outpatient clinic of a university hospital and were diagnosed with PD. Healthy subjects similar to the patient group in terms of age, gender, weight, and BMI constituted the control group in this study. The Panic-Agoraphobia Scale (PAS) was applied to all subjects in both groups. Blood samples were collected to measure plasma nesfatin-1 level by using ELISA method. Results: Mean plasma nesfatin-1 level (4.66 +/- 2.39 ng/ml in patient group, 2.13 +/- 1.52 ng/ml in control group) was higher in patients with PD than in the control group (p<0.001). A positive correlation between PAS scores and plasma nesfatin-1 levels was found in the patients with PD. Conclusion: There may be a relationship between disease severity and plasma nesfatin-1 levels in panic disorder patients. Future studies investigating this relationship are needed.
  • [ X ]
    Öğe
    Serum adiponectin and resistin levels in patients with obsessive compulsive disorder
    (Elsevier, 2012) Ari, Mustafa; Ozturk, Oktay Hasan; Bez, Yasin; Arica, Secil; Can, Yesim; Erduran, Dudu
    We aimed to investigate the changes in serum adiponectin and resistin levels in patients with obsessive compulsive disorder and control groups. The serum adiponectin and resistin levels of 29 patients (16 females, 13 males) with obsessive compulsive disorder and weight, age and sex-matched 31 healthy controls (17 females, 14 males) were determined. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) was applied to all groups. ELISA method was used to measure adiponectin and resistin levels. The mean adiponectin level was 11.92 +/- 2.04 ng/ml and resistin level was 13.23 +/- 2.78 ng/ml in obsessive compulsive disorder group, while it was 18.81 +/- 5.24 ng/ml and 8.17 +/- 2.53 ng/ml in control group. Changes in plasma adiponectin and resistin levels in obsessive compulsive disorder may have implications about possible cardiovascular and metabolic abnormalities seen in obsessive compulsive patients. (C) 2011 Published by Elsevier B.V.